The Global Constrained Peptide Drugs Market Size is predicted to witness a 31.56% CAGR during the forecast period for 2023-2031.
Polypeptide chains with cyclic rings make up cyclic peptides. The ring structure can be created by joining the ends of the peptide together with an amide bond or another chemically stable bond such as lactone, ether, thioether, disulfide, and so on. Many biologically active cyclic peptides are produced through the process known as N-to-C (or head-to-tail) cyclization, which involves the production of amide bonds between the amino and carboxyl termini.
In clinical settings, a number of cyclic peptides from nature are employed. A variety of factors, such as an increase in the number of older individuals, an increase in the prevalence of chronic diseases, and a rise in patient knowledge of peptide therapies breakthroughs, are projected to drive the development of the market for peptide therapeutics.
The increase in product development and technical advancements is another prominent market trend that is projected to boost expansion in the future years. At first, COVID-19 had a significant effect on market expansion. For instance, according to a Frontiers article from May 2022, the pandemic led to the development of many peptide-based vaccines and medication candidates, which had a favourable impact on the management of COVID-19 infections. As a result, the pandemic greatly influenced the market's expansion. The market, however, is anticipated to have steady development during the projected period now that the epidemic has passed.
Competitive Landscape:
Some of the major key players in the Constrained Peptide Drugs Market are:
• Aileron Therapeutics, Inc.
• Bicycle Therapeutics plc
• Spexis AG
• Protagonist Therapeutics Inc.
• Santhera Pharmaceuticals
• Union Chimique Belge S.A. (UCB)
• Creative Peptides
• Biosynth (Pepscan)
• Pepticom Ltd.
• PeptiDream Inc.
• Bio-Synthesis Inc
• CPC Scientific Inc.
• Circle Pharma
• Zealand Pharma
• Chugai Pharmaceutical Co. Ltd.
Market Segmentation:
The Constrained Peptide Drugs market is segmented on the basis of Peptide Type and Potential Product. By Peptide Type, the market is segmented into Disulfide-Rich Peptides (DRPs) and Cyclic Peptides. On the basis of Potential Products, the market is segmented into BT5528, Rusfertide (PTG-300), PN-943, PN-235, and Zilucoplan (RA101495).
Based On Peptide Type, The Disulfide-Rich Peptides (Drps) Segment Is Accounted As A Noteworthy Contributor In The Constrained Peptide Drugs Market
The pipeline-restricted peptides with either few or no licenced medications for the condition are included in the disulfide-rich peptides (DRPs) category, which is predicted to dominate the worldwide constrained peptide pharmaceuticals market. A group of peptides known as DRPs have many intramolecular disulfide bonds, which give them exceptional structural stability and bioactive characteristics. Due to their distinctive disulfide link configuration, these peptides are also known as cysteine-rich or cystine-knot peptides.
The Zilucoplan (RA101495) Segment Witnessed Growth At A Rapid Rate
The Zilucoplan (RA101495) segment is projected to grow rapidly in the global constrained peptide drugs market. UCB Pharmaceuticals is creating Zilucoplan to treat myasthenia gravis (MG) and other complement-mediated diseases. An autoimmune condition called myasthenia gravis damages the neuromuscular junction and results in tiredness and muscle weakening. Zilucoplan is made to block the complement system's C5 protein, which is involved in inflammation and the immunological response.
The North America Constrained Peptide Drugs Market Holds A Significant Revenue Share In The Region
Due to the growing need for anti-cancer medications, the rising incidence of cardiovascular disorders and other diseases, as well as the high demand for peptide and anticoagulant drugs, North America is anticipated to hold a sizable share of the global market for these medications throughout the forecast period. Aspects such as the rising burden of cancer and the rising frequency of cardiovascular diseases are expected to increase demand for peptide and anticoagulant medications.
Constrained Peptide Drugs Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 31.56 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Peptide Type and Potential Product |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Aileron Therapeutics Inc., Bicycle Therapeutics plc, Spexis AG, Protagonist Therapeutics Inc., Santhera Pharmaceuticals, Union Chimique Belge S.A. (UCB), Creative Peptides, Biosynth (Pepscan), Pepticom Ltd., PeptiDream Inc., Bio-Synthesis Inc, CPC Scientific Inc., Circle Pharma, Zealand Pharma, and Chugai Pharmaceutical Co. Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
